Evaluation of pentoxifylline effect in treatment of Ankylosis Spondylitis patients referred to Hazrat Rasool Akram Hospital

Ankylosing spondylitis (AS) is a spondyloarthropathy of unknown etiology, with widespread effect on axial and peripheral skeleton. The aim of this study was determination of Pentoxifylline effect on BASDAI number of uncontrolled AS patients in Rasool-e-Akram hospital rheumatology clinic. This pilot study was performed on 30 patients with ankylosis spondylitis with BASDAI ≥ 4 without attention to previous medical treatment. Pentoxifylline tablets administered 400 mg TDS and patients evaluated at 6 and 12 weeks after treatment. Data were analyzed by Paired T test and p<0.05 was significant. 30 patients (26 = Male (86.7%), 4 = Female (13.3%)) with Ankylosing spondylitis was evaluated. Mean age of patients was 32.42±8.14. mean ± standard deviation of BASDAInumber in our patients was 6.53±1.72 at baseline, which decreased to 5.17±1.58 at 6 weeks and 4.88±1.66 at 12 weeks of treatment.(P=0/000) Between BASDAI before and after treatment with Pentoxifylline differences was significant. Pentoxifylline can be advised for uncontrolled AS patients regardless of current or previous treatment.